Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIOMET for accelerated maturation in early pubertal girls
2021-006766-21Phase 2Active
- Sponsor
- Hospital Universitari de Girona Dr. Josep Trueta
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of spironolactone, pioglitazone and metformin in precocious puberty and Not applicable (not a disease) (2 arms), sponsored by Hospital Universitari de Girona Dr. Josep Trueta. Primary endpoint: Bone age advancement. Started May 2022; status: active.
02
Drugs
spironolactonepioglitazonemetformin
03
Conditions
precocious pubertyNot applicable (not a disease)
Beyond the preview
Go deeper on 2021-006766-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006766-21.